切换至 "中华医学电子期刊资源库"

中华临床实验室管理电子杂志 ›› 2019, Vol. 07 ›› Issue (04) : 214 -218. doi: 10.3877/cma.j.issn.2095-5820.2019.04.006

所属专题: 文献

实验研究

血清胃蛋白酶原和胃泌素17在胃癌及萎缩性胃炎中的诊断价值研究
安云飞1, 丁霏1, 蔡蓓1, 赵文玲1, 胡静1, 黄卓春1, 李立新1,()   
  1. 1. 610041 成都,四川大学华西医院实验医学科
  • 收稿日期:2018-08-02 出版日期:2019-11-28
  • 通信作者: 李立新

Study on the diagnostic value of serum pepsinogen and gastrin-17 in gastric cancer and atrophic gastritis

Yunfei An1, Fei Ding1, Bei Cai1, Wenling Zhao1, Jing Hu1, Zhuochun Huang1, Lixin Li1,()   

  1. 1. Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu 610041, China
  • Received:2018-08-02 Published:2019-11-28
  • Corresponding author: Lixin Li
  • About author:
    Corresponding author: Li Lixin, Email:
引用本文:

安云飞, 丁霏, 蔡蓓, 赵文玲, 胡静, 黄卓春, 李立新. 血清胃蛋白酶原和胃泌素17在胃癌及萎缩性胃炎中的诊断价值研究[J/OL]. 中华临床实验室管理电子杂志, 2019, 07(04): 214-218.

Yunfei An, Fei Ding, Bei Cai, Wenling Zhao, Jing Hu, Zhuochun Huang, Lixin Li. Study on the diagnostic value of serum pepsinogen and gastrin-17 in gastric cancer and atrophic gastritis[J/OL]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2019, 07(04): 214-218.

目的

探讨血清中胃蛋白酶原(pepsinogen,PG)和胃泌素-17(gastrin-17,G-17)在非萎缩性胃炎、萎缩性胃炎及胃癌中的水平变化及临床价值。

方法

应用酶联免疫吸附试验检测37例非萎缩性胃炎、37例萎缩性胃炎和65例胃癌患者血清胃蛋白酶原Ⅰ(PGⅠ)、胃蛋白酶原Ⅱ(PGⅡ)、G-17的水平和PGⅠ/PGⅡ的比值(PGR)。

结果

萎缩性胃炎组的PGⅠ水平和PGR值较非萎缩性胃炎组明显降低(P<0.05);胃癌组的PGⅠ水平和PGR值较非萎缩性胃炎组及萎缩性胃炎组明显降低(P<0.05);胃癌组的PGⅡ水平较非萎缩性胃炎组明显升高(P<0.05);胃癌组的G-17水平较萎缩性胃炎和非萎缩性胃炎组明显升高(P<0.05);胃癌组胃窦癌比胃体癌组者的血清G-17水平明显升高(P<0.05)。

结论

胃蛋白酶原和胃泌素可以作为筛查萎缩性胃炎和胃癌的血清学指标,血清胃泌素-17对于鉴别胃窦和胃体癌有较大的临床价值。

Objective

To investigate the level changes and clinical value of serum pepsinogen (PG) and gastrin-17 (Gastrin-17) in non-atrophic gastritis, atrophic gastritis and gastric cancer.

Method

Pepsinogen Ⅰ (PGⅠ), pepsinogen Ⅱ (PGⅡ), gastrin-17 (G-17) and the PGⅠ/PGⅡ (PGR) levels were measured in 37 patients with non-atrophic gastritis, 37 patients with atrophic gastritis and 65 patients with gastric cancer by enzyme-linked immunosorbent assay.

Results

The PGⅠand PGR in the atrophic gastritis group were significantly lower than those in the non-atrophic gastritis group (P<0.05). The PGⅠand PGR levels in the gastric cancer group were significantly lower than those in non-atrophic gastritis group and atrophic gastritis group (P<0.05). The level of PGⅡ in the gastric cancer group was significantly higher than that in the non-atrophic gastritis group (P<0.05). The G-17 in the gastric cancer group was significantly higher than that that in the atrophic gastritis and non-atrophic gastritis group (P<0.05). The G-17 in the gastric antrum cancer group was significantly higher than that in the gastric body cancer group (P<0.05).

Conclusions

Pepsinogen and gastrin can be used as serological markers for screening atrophic gastritis and gastric cancer. Serum gastrin-17 has great clinical value in distinguishing gastric antrum and gastric body cancer.

表1 血清PGⅠ、PGⅡ、PGR及G-17水平在良恶性胃病患者组间比较分析[中位数(四分位间距)]
表2 单纯萎缩及萎缩伴肠化患者血清PGⅠ、PGⅡ、PGR及G-17水平比较[中位数(四分位间距)]
表3 胃窦及胃体胃癌组患者血清PGⅠ、PGⅡ、PGR及G-17水平比较[中位数(四分位间距)]
表4 血清PGⅠ、PGⅡ、PGR及G-17诊断胃癌、萎缩性胃炎和胃体胃癌最佳临界值及对应的灵敏度、特异性和AUC(各指标按AUC大小排列)
图1 1/PGⅠ、PGⅡ、1/PGR和G-17诊断胃癌的ROC曲线
图2 PGⅠ、PGR、1/PGⅡ和G-17诊断萎缩性胃炎的ROC曲线
图3 血清PGⅠ、PGⅡ、PGR和G-17用于诊断胃窦和胃体胃癌的ROC曲线
1
Samlof IM, Varis K, Ihamaki T, et a1. Relationships among serum pepsinogen I,serum pepsinogen Ⅱ, and gastric mueosal histology. A study in relatives of patients with pernicious anemia[J]. Gastroenterology, 1982,83(1Pt2):204-209.
2
刘慧杰,高华,董明,等. 胃蛋白酶原C基因多态与胃癌遗传易感性的相关研究[J]. 中华医学杂志, 2001,81(15):947-948.
3
Shafaghi A, Mansour-Ghanaei F, Joukar F, et al. Serum gastrin and the pepsinogen Ⅰ/Ⅱ ratio as markers for diagnosis of premalignant gastric lesions[J]. Asian Pac J Cancer Prev, 2014,14(6):3931-3936.
4
Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000[J]. CA Cancer J Clin, 2000,50(1):7-33.
5
Watson SA, Grabowska AM, E1-Zaatari M, et a1. Gastrin-active participant or bystander in gastric carcinogenesis[J]. Nat Rev Cancer, 2006,6(12):936-946.
6
Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells[J]. Nat Rev Cancer, 2005,5(3):223-231.
7
Suzuki H, Hibi T, Marshall BJ. Helicobacter pylori: present status and future prospects in Japan[J]. J Gastroenterol, 2007,42(1):1-15.
8
Suzuki H, Iwasaki E, Hibi T. Helicobacter pylori and gastric cancer[J]. Gastric Cancer, 2009,12(2):79-87.
9
Fock KM, Talley N, Moayyedi P, et al. Asia-Pacific consensus guidelineson gastric cancer prevention[J]. J Gastroenterol Hepatol, 2008,23(3):351-365.
10
Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infectionand the development of gastric cancer[J]. N Engl J Med, 2001,345(11):784-789.
11
Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication toprevent gastric cancer in a high-riskregion of China: a randomizedcontrolled trial[J]. JAMA, 2004,291(2):187-194.
12
王雪华,曹燕,张剑宏,等. 血清胃蛋白酶原联合胃泌素测定在胃癌及萎缩性胃炎中的诊断价值[J/CD]. 中华临床医师杂志(电子版), 2015,5(9):1824-1827.
13
朱春平,赵建业,申晓军,等. 血清胃泌素-17联合胃蛋白酶原检测对胃癌诊断价值的多中心临床研究[J]. 中华消化内镜杂志, 2017,34(1):19-23.
14
张洁,刘怡菁,王震华. 血清胃蛋白酶原Ⅰ、Ⅱ及其比值诊断效能评价[J]. 临床研究, 2015,6(16):860-863.
15
马颖杰,曹邦伟,李琴,等. 胃癌患者及其化疗后胃蛋白酶原与胃泌素变化的临床意义[J]. 临床和实验医学杂志, 2014,13(3):186-189.
[1] 安杰, 牛云峰, 刘伟. LINC00520 通过miR-519b-3p/HIF1A 轴促进胃癌的侵袭转移[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 430-436.
[2] 许革新, 何琦, 毛智军, 普彦淞, 杨淦傑, 王建华. 我国胃肿瘤外科治疗现状及发展趋势—基于CiteSpace的可视化分析[J/OL]. 中华普通外科学文献(电子版), 2024, 18(05): 350-356.
[3] 李国新, 陈新华. 全腹腔镜下全胃切除术食管空肠吻合的临床研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 1-4.
[4] 陈方鹏, 杨大伟, 金从稳. 腹腔镜近端胃癌切除术联合改良食管胃吻合术重建His角对术后反流性食管炎的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 15-18.
[5] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[6] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[7] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[8] 任佳, 马胜辉, 王馨, 石秀霞, 蔡淑云. 腹腔镜全胃切除、间置空肠代胃术的临床观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 31-34.
[9] 王露, 周丽君. 全腹腔镜下远端胃大部切除不同吻合方式对胃癌患者胃功能恢复、并发症发生率的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 92-95.
[10] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[11] 梁孟杰, 朱欢欢, 王行舟, 江航, 艾世超, 孙锋, 宋鹏, 王萌, 刘颂, 夏雪峰, 杜峻峰, 傅双, 陆晓峰, 沈晓菲, 管文贤. 联合免疫治疗的胃癌转化治疗患者预后及术后并发症分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 619-623.
[12] 刘海旺, 施海, 尚利峰. 不同吻合器在腹腔镜远端胃癌根治术Roux-en-Y式吻合中的应用对比[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 643-646.
[13] 许杰, 李亚俊, 冯义文. SOX新辅助化疗后腹腔镜胃癌D2根治术与常规根治术治疗进展期胃癌的近期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 647-650.
[14] 贺斌, 马晋峰. 胃癌脾门淋巴结转移危险因素[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 694-699.
[15] 张立俊, 孙存杰, 胡春峰, 孟冲, 张辉. MSCT、DCE-MRI 评估术前胃癌TNM 分期的准确性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 519-523.
阅读次数
全文


摘要